Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.

被引：0
|
作者：
Cheng, Jia-Tao
Yang, Jin-Ji
Wu, Yi-Long
机构：
[1] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20726
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer
    Piotrowska, Zofia
    Sequist, Lecia V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 419 - 421
  • [2] The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib.
    Kang, Jin
    Li, Xiang-Meng
    Cheng, Jia-Tao
    Chen, Huajun
    Zhang, Xuchao
    Tu, Hai-Yan
    Zhou, Qing
    Wu, Yi-Long
    Yang, Jin-Ji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Clinical Implications of Additional Mutations Detected by Next-Generation Sequencing in EGFR-Mutant Lung Adenocarcinoma
    Kadauke, S.
    Hiemenz, M. C.
    Deshpande, C.
    Litzky, L. A.
    Roth, D. B.
    Ahmed, S.
    Aggarwal, C.
    Morrissette, J.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 759 - 759
  • [4] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
    Lee, Jiyun
    Piotrowska, Zofia
    Soo, Ross
    Cho, Byoung Chul
    Lim, Sun Min
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [5] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
  • [6] Clinical Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs Followed by Subsequent Osimertinib
    Yao, Y.
    Cheng, J.
    Kang, J.
    Li, X.
    Chen, H.
    Zhou, Q.
    Xu, C.
    Zhang, X.
    Su, J.
    Yan, H.
    Wu, Y.
    Yang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S671 - S671
  • [7] Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma
    Goldberg, Sarah B.
    Narayan, Azeet
    Carriero, Nicholas J.
    Nemati, Roxanne
    Bommakanti, Ananth
    Wurtz, Anna
    Boffa, Daniel J.
    Decker, Roy H.
    Herbst, Roy S.
    Juergensmeier, Juliane M.
    Politi, Katerina A.
    Gettinger, Scott N.
    Patel, Abhijit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Effect of P. gingivalis on osimertinib resistance in EGFR-mutant lung cancer
    Li, Wendong
    Rotter-Maskowitz, Aviva
    Zhang, Keqiang
    Massarelli, Erminia
    Potempa, Jan
    Straussman, Ravid
    Raz, Dan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Mechanisms of resistance for osimertinib for patients with EGFR-mutant lung cancer: MD Anderson Cancer Center single institution experience with osimertinib resistance
    Le, Xiuning
    Negrao, Marcelo Vailati
    Nilsson, Monique
    Robichaux, Jacqulyne
    Roarty, Emily
    Rinsurongkawong, Waree
    Glisson, Bonnie
    Zhang, Jianjun
    Heymach, John V.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [10] Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs
    Lee, Choong-kun
    Kim, Sora
    Lee, Jae Seok
    Lee, Jeong Eun
    Kim, Sung-moo
    Yang, In Seok
    Kim, Hye Ryun
    Lee, Jeong Ho
    Kim, Sangwoo
    Cho, Byoung Chul
    [J]. LUNG CANCER, 2017, 113 : 106 - 114
12345